User:Mr. Ibrahem/Denileukin diftitox

Denileukin diftitox, sold under the brand name Ontak, is a medication used to treat cutaneous T-cell lymphoma (CTCL). It is used for certain cases that have failed other treatments. It is given by injection into a vein.

Common side effects include tiredness, fever, nausea, diarrhea, joint pain, headache, and rash. Other side effects may include capillary leak syndrome, low blood pressure, kidney problems, infections, blood clots, pancreatitis, and pulmonary edema. It is a fusion protein that combines human interleukin-2 (IL-2) with diphtheria toxin fragments.

Denileukin diftitox was approved for medical use in the United States in 1999. When launched it cost about 25,000 to 50,000 USD per person treated. It; however, was discontinued in 2014 due to difficulties with manufacturing.